AI in drug discovery

Digital

Recursion, Exscientia, and AI drug discovery’s moment of tru...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

Digital

AI as an inventor: Defining ownership in the pharma sector

The global pharmaceutical industry is witnessing a surge in innovation, with the industry experiencing a 5% growth in the number of AI-related patent applications in Q1 2024 and

Digital

People need to know how to use AI now

With the implementation of advancing technologies in industry comes the parallel need for suitable upskilling of the workforce – but this doesn’t as yet always pan out, and in today’s pharm

News

Recursion Pharma and Exscientia company logos

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued

Digital

Drug development and compliance: 4 Ways AI is impacting phar...

The pharmaceutical industry has long been reliant on rigorous research and development processes to bring life-saving drugs to market.

News

Noubar Afeyan, founder and chief executive of Flagship Pioneering

Flagship closes $3.6bn biotech fund, with a focus on AI

Venture capital group Flagship Pioneering has raised $2.6 billion to support the development of around 25 startups operating in human health, sustainability, and artificial intelligence, wi

Recursion, Exscientia, and AI drug discovery’s moment of tru...

AI as an inventor: Defining ownership in the pharma sector

People need to know how to use AI now

AI biotechs Exscientia and Recursion agree $688m merger

Drug development and compliance: 4 Ways AI is impacting phar...

Flagship closes $3.6bn biotech fund, with a focus on AI

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

AI in drug discovery

Editor's Picks